CN1491642A - Adhesive film agent and its preparing method - Google Patents
Adhesive film agent and its preparing method Download PDFInfo
- Publication number
- CN1491642A CN1491642A CNA021465258A CN02146525A CN1491642A CN 1491642 A CN1491642 A CN 1491642A CN A021465258 A CNA021465258 A CN A021465258A CN 02146525 A CN02146525 A CN 02146525A CN 1491642 A CN1491642 A CN 1491642A
- Authority
- CN
- China
- Prior art keywords
- medicated layer
- membranous patch
- medicine
- plasticizer
- described membranous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 title claims description 8
- 239000002313 adhesive film Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title description 8
- 239000003814 drug Substances 0.000 claims abstract description 72
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 239000000463 material Substances 0.000 claims abstract description 19
- 239000004014 plasticizer Substances 0.000 claims abstract description 12
- 239000000853 adhesive Substances 0.000 claims abstract description 8
- 230000001070 adhesive effect Effects 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims description 22
- 239000004480 active ingredient Substances 0.000 claims description 18
- 239000011159 matrix material Substances 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 14
- 239000003292 glue Substances 0.000 claims description 14
- -1 Pioloform Polymers 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 239000004615 ingredient Substances 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 229940126680 traditional chinese medicines Drugs 0.000 claims description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 235000008216 herbs Nutrition 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims description 2
- 238000005520 cutting process Methods 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229920001059 synthetic polymer Polymers 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 206010013786 Dry skin Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 13
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 230000017531 blood circulation Effects 0.000 abstract description 7
- 230000028327 secretion Effects 0.000 abstract description 3
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 44
- 239000010410 layer Substances 0.000 description 24
- 210000003516 pericardium Anatomy 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 7
- 238000011068 loading method Methods 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229940114124 ferulic acid Drugs 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000032630 lymph circulation Effects 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 4
- 241000628997 Flos Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 4
- 235000001785 ferulic acid Nutrition 0.000 description 4
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 4
- 230000037317 transdermal delivery Effects 0.000 description 4
- 235000015511 Liquidambar orientalis Nutrition 0.000 description 3
- 235000003143 Panax notoginseng Nutrition 0.000 description 3
- 241000180649 Panax notoginseng Species 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 241000736148 Styrax Species 0.000 description 3
- 239000004870 Styrax Substances 0.000 description 3
- 235000000126 Styrax benzoin Nutrition 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229940126678 chinese medicines Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 235000010603 pastilles Nutrition 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- 241000717739 Boswellia sacra Species 0.000 description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 2
- 241000218176 Corydalis Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004863 Frankincense Substances 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 241001057584 Myrrha Species 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000013985 cinnamic acid Nutrition 0.000 description 2
- 229930016911 cinnamic acid Natural products 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010031256 Osteomyelitis chronic Diseases 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000000895 extractive distillation Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 210000004220 fundus oculi Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- ZBELDPMWYXDLNY-UHFFFAOYSA-N methyl 9-(4-bromo-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Br)C=C1F ZBELDPMWYXDLNY-UHFFFAOYSA-N 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The adhesive film preparation consists of back lining material, medicine layer and protecting film, and the medicine layer is fixed to the back lining material via two opposite adhesive edges or some regularly distributed points around it. The medicine layer consists of skeleton supplementary material in 20-30 wt%, effective medicine components in 60-75 wt% and plasticizer in 5-10 wt%, and is 0.13-0.5 cm in thickness. The adhesive film preparation has no influence on the blood circulation, metabolism and secretion of the skin in the applied part, no allergy, great medicine carrying amount, fast medicine release, effective transdermal absorption for great concentration of medicine in blood to reach the aim of curing internal disease via external application. The preparation process of the adhesive film preparation is also disclosed.
Description
Technical field
The present invention relates to a kind of membranous patch, specifically, is a kind of novel form between paster agent and membrane, not only go for Western medicine, and more be applicable to Chinese medicine, and the preparation method of this membranous patch.
Technical background
Transdermal therapeutic system for administering, be that a kind of medicine enters the body circulation through skin by blood vessel or lymphatic vessel and produces the therapeutic modality of whole body therapeutic effect, it both had been suitable for local wound or affected skin, muscle, joint, mucosa being treated, and also was adapted to pass through blood circulation rice and produced the whole body therapeutic effect and be used for the treatment of various internal diseases.Be applicable to the dosage form of this therapy system traditional ointment, plaster, ointment, gel, ointment arranged, it is film reservoir devices, framework controlled release type and pair micro-reservoirs type three classes that present modern percutaneous drug administration preparation is divided into three kinds, and wherein framework controlled release type transdermal delivery system is divided into polymer backbone type and adhesive matrix type according to the difference of framework material again.These percutaneous dosing dosage forms, percutaneous dosing blood drug level steadily, lasting, the peak-paddy phenomenon of no oral or injecting drug use blood drug level has reduced toxic and side effects; Percutaneous dosing makes medicine without gastrointestinal tract and liver, so can avoid pH in the gastrointestinal tract and enzyme thereof to the destruction of medicine and the first pass effect of Degradation and liver, has reduced the individual variation that causes thus; Patient does not have for a long time the misery of taking medicine, having an injection.However, these transdermal delivery systems all contain glue,medicinal in every way at present, or the adhesive layer of direct and contact skin, or the pressure-sensitive adhesive layer of pastille is arranged, and perhaps adhesive and medicament mixed are made adhesive matrix type transdermal delivery system; Or around containing the drug depot skeleton, use a circle to use adhesive.But have a common ground be exactly these transdermal delivery systems all be closely to adhere to patch on the skin by glue,medicinal such as polyacrylate, polysiloxane-based and polyisobutylene class pressure sensitive adhesive, because glue,medicinal is to the stimulation of skin, institute is so that skin all produces irritated to some extent after patient's medication.Often make patient skin irritated or do not feel well, limited patient's selection and used, more should not paste for a long time.The more important thing is during percutaneous dosing patch and skin close adhesion are caused the airtight of skin, badly influence the drainage of the homergy and the secretions of local skin, influenced the absorption of skin medicine.In addition, effective components of Chinese medicinal is dispersed in the glue,medicinal stick, the mixing of effective components of Chinese medicinal and macromolecule glue just, drug loading is few, rate of release is slow, blood drug level is low, thereby pharmaceutically active ingredient enters the amount performance whole body therapeutic effect of blood or lymph circulation in badly influencing by skin, therefore can only treat the body surface disease, not reach the requirement of treatment viscera disease.Equally, though membrane does not contain glue,medicinal, but because the common thickness of membrane only is 0.1-0.2mm, generally be no more than 1mm, limited the drug loading of membrane, more can't be applicable to Chinese medicine, this is because a little less than the herbal nature, thereby must could really play the purpose that percutaneous dosing acts on whole body realization inner disease outer treat by strengthening dosage.
Because the above-mentioned defective of exterior-applied formulation existence at present, make patient's medication inconvenience, when active component is Chinese medicine, more can't be used for effective whole body therapeutic effect can not be provided, so can't really realize Chinese medicine percutaneous dosing treatment viscera disease, even clinical use, effect are also very undesirable, seriously limited the application of Chinese medicine percutaneous dosing therapy.Therefore, in percutaneous drug administration preparation, need a kind of irritated percutaneous dosing dosage form that improves skin absorbs of patient skin that overcomes, treat the Chinese medicine exterior-applied formulation that the field more needs a kind of drug loading height, the percutaneous dosing that reaches blood or lymph circulation can effectively be provided at the Chinese medicine percutaneous dosing.
Summary of the invention
One object of the present invention has just provided and a kind ofly can overcome patient skin defective hypersensitive and improve the membranous patch that skin absorbs is beneficial to life-time service.
Another object of the present invention just provide a kind of be fit to the active ingredient of Chinese herbs percutaneous absorb arrive blood or lymph circulation pad pasting, this pad pasting drug loading is big and skin absorbs is good, the Chinese medicine percutaneous is absorbed enter blood or lymph circulation, make Chinese medicine treat viscera disease by percutaneous dosing thereby really realized having had the whole body therapeutic effect.
Another object of the present invention has provided the preparation method of this pad pasting.
Pad pasting of the present invention is made up of back lining materials, protecting film and medicated layer, and the back lining materials of pad pasting just has sticker to fix medicated layer at two parallel edges of medicated layer, and two other edge does not have sticker; Perhaps back lining materials only around medicated layer fixed point rather than four limits have sticker to fix medicated layer, these fixed points comprise four angle points and every limit mid point or on every limit more multiple spot are arranged.When this improvement makes pad pasting of the present invention on sticking on skin, also be to be fixed on the skin by above-mentioned limit or fixed point, make not exclusively closely skin adherent of medicated layer four limits, thereby do not influence the homergy of the local skin that sticks and the eliminating of secretions, be beneficial to that to stick skin place blood circulation normal, it is irritated that life-time service does not make skin produce, and it is more comfortable that patient's life-time service is also felt.
The used medicated layer of pad pasting of the present invention is made up of matrix type adjuvant, effective ingredient and plasticizer, and pastille does not stick with glue agent.Wherein said matrix type adjuvant comprises all pharmaceutically acceptable matrix type adjuvants, include but not limited in natural polysaccharide and synthetic polymer such as polyvinyl alcohol, Pioloform, polyvinyl acetal, polyvinylpyrrolidone, polyacrylate or the polyacrylamide one or more, preferably polyethylene alcohol; Plasticizer wherein includes but not limited to one or more in glycerol, triacetyl glycerine, ethylene glycol, the sorbitol phthalic acid ester, preferably glycerine.
The matrix type adjuvant accounts for 20-30% in the pad pasting medicated layer of the present invention, preferred 23-25%; Effective components of Chinese medicinal accounts for 60～75%, preferred 68-70%, and plasticizer accounts for 5-10%, preferred 6-8%.
The used filmogen of pad pasting of the present invention has been selected the matrix type adjuvant for use, this selection has effectively overcome big mixing of synthetic high polymer glue,medicinal of middle pharmaceutically active ingredient and viscosity and has been unfavorable for the defective that it discharges, the network structure that while matrix type adjuvant is had, can be so that mesh adheres to middle pharmaceutically active ingredient (drug loading is big) in a large number, owing to be not subjected to the adhesion of the bigger synthetic high polymer glue of viscosity, when on the internal organs skin that spreads on pathological changes outside the pad pasting, medicine can discharge from mesh is free fast, enter the body circulation through subcutaneous blood capillary absorption, destruction and degraded without gastrointestinal and liver enzyme, blood drug level is high and lasting, reaches the effect of inner disease outer treat.
The thickness of pad pasting medicated layer of the present invention can reach 0.13-0.5cm, has increased drug loading greatly.
Pad pasting medicated layer of the present invention is because drug loading is big, so go for active ingredient of Chinese herbs.The inventor finds that in development process the extract great majority of middle pharmaceutically active ingredient have lipotropy, penetrate epidermis so be beneficial to very much.When Chinese medicine is made active component, can be single medicinal material or kinds of traditional Chinese medicines, these Chinese medicines can be fine powdered such as Borneolum Syntheticum aromatic and inducing resuscitation medicine, and powder can be that the millimeter level is to nanoscale; It also can be the middle pharmaceutically active ingredient that extracts processing through the various extracting method of the field of Chinese medicines.
Pad pasting medicated layer of the present invention does not contain surfactant and penetration enhancers.But the existing therapeutical effect of aromatics medicine in the middle pharmaceutically active ingredient is again good natural percutaneous promoter, and the effect of blood vessel dilating is arranged, and has played the effect of penetration enhancers.These aromatics Chinese medicines comprise but are not defined as Borneolum Syntheticum etc.
Back lining materials used in the pad pasting of the present invention generally has polrvinyl chloride, polyethylene, aluminium foil, polypropylene or non-woven fabrics, and used protecting film can be hard gauze, cellophane or plastic sheeting such as polyethylene, polystyrene, polypropylene etc. in the pad pasting of the present invention.
The preparation of pad pasting of the present invention is only two parallel edges of medicated layer to be sticked with glue agent to be fixed on the back lining materials, perhaps fixed point around the medicated layer is comprised four angle points and every limit mid point or stick with glue agent on there is more multiple spot on every limit being fixed on the back lining materials.
The preparation of the medicated layer in the pad pasting of the present invention is to adopt MULTILAYER COMPOSITE thickening method to realize the thickness of pad pasting medicated layer of the present invention.
When the effective ingredient in the medicated layer is Chinese medicine, can at first Chinese medicine be pulverized and grind to form the millimeter level to nano level Powdered, perhaps extracted at the characteristic of middle pharmaceutically active ingredient.When the preparation medicated layer, pharmaceutically active ingredient changes easily and loses activity at high temperature in considering, especially the volatile effective ingredient in the Chinese medicine aromatics medicine is lost easily, so selected 25 ℃-40 ℃ for use at drying steps, preferred 35 ℃.
The preparation method of Chinese medicine pad pasting of the present invention comprises the following steps:
Make thick paste according to the corresponding prescription of treatment various diseases according to various extracting method, with matrix type adjuvant 20-30%, preferred 23-25%, contained Chinese medicine millimeter level are to nanometer grade powder or Chinese medicine extract 60～75%, preferred 68-70%, and contained plasticizer 5-10%, preferred 6-8% fully mixes, and being stirred to does not have till the bubble; Suppress film forming with film-making machine then; multilayer film stacks the thickness of 0.13-0.5cm; after the 25-40 ℃ of drying; with medicated layer one side according to above-mentioned both sides fixed form or four jiaos of fixed points or every limit mid points or have more on every limit that multiple spot adheres on the back lining materials; the other one side of medicated layer adds protecting film, and the cutting packing forms.
Pad pasting of the present invention can be according to different sick kinds, adopt different Chinese medicine compound, pulverizing grinds to form millimeter to nanometer powder or carry out effective components of Chinese medicinal extraction and be condensed into thick paste being mixed with the Chinese medicine medicated layer, on the corresponding skin surface of external application, can be so that the middle pharmaceutically active ingredient percutaneous in the pad pasting reach in blood or the lymph circulation, thus reach the purpose of inner disease outer treat.This point inventor is verified by the Transdermal absorption test.So Chinese medicine pad pasting of the present invention can be fit to be applied to the prevention and the treatment of different internal organs diseases, these diseases comprise:
(1) control angina pectoris external application pareordia.
(2) control cerebrovascular disease external application cervical region trunk.
(3) prevent and treat chronic hepatitis, liver cirrhosis, fatty liver external application hepatic region.
(4) prevent and treat gastritis, antral gastritis, flatulence, stomachache, dyspepsia external application gastric area.
(5) external application lower abdomens such as control prostatitis, prostate hyperplasia, cystitis.
(6) prevent and treat chronic nephritis, nephrotic syndrome external application kidney district.
(7) prevent and treat diabetes external application human pancreas district.
(8) control women's chronic pelvic inflammatory disease and adnexitis external application lower abdomen.
(9) prevent and treat hypertension, hyperlipidemia, arteriosclerosis external application body surface trunk portion.
(10) treatment facial paralysis, vasospasmotic headache external application affected part.
Chinese medicine pad pasting of the present invention also is fit to be applied to different part of human body or body surface pathological changes:
(11) prevent and treat fundus oculi disease and two outsides of the outer disease external application of eye temple.
(12) control person in middle and old age hypermetropia, adolescent myopia external application temple.
(13) prevent and treat rhinitis, sinusitis external application nose or forehead position.
(14) treatment chronic ulcer of lower extremity, the phlebitis of lower extremities, lower limb vascular ischemic diseases external application lower limb affected part.
(15) treat local swelling, pain such as early stage skin ulcer, furuncle, carbuncle, mosquito bite, external application affected part such as itch.
(16) anti-treating acute and chronic arthritis, rheumatic arthritis, rheumatoid arthritis external application pathological changes joint.
(17) treatment chronic osteomyelitis external application affected part.
(18) pain relieving, antiinflammatory, the detumescence external application wound of operation back open wound.
(19) pain relieving, antiinflammatory, detumescence, the protection wound external application wound of the open wound of skin surface and soft tissue.
(20) human body soft tissue closed injury is as athletic injury (fall, beat, pound, turn round etc.) pain relieving, antiinflammatory, detumescence, functional rehabilitation external application wound.
For pad pasting of the present invention is described better, following examples have been enumerated the Chinese medicine patch membrane of preventing and treating coronary heart disease, but it can not be interpreted as the Chinese medicine pad pasting that just is limited to treatment coronary heart disease.
Embodiment 1. prevents and treats the preparation of guarantor's pericardium Chinese medicine pad pasting of coronary heart disease
A) take by weighing each medicinal raw material in the prescription according to following consumption:
Rhizoma Chuanxiong 234g Lignum Santali Albi 87g Radix Curcumae 87g Lignum Aquilariae Resinatum 45g Rhizoma Cyperi 87g
Lignum Dalbergiae Odoriferae 87g Olibanum 87g Myrrha 87g Flos Chrysanthemi 129g Flos Caryophylli 45g
Radix Angelicae Sinensis 87g Radix Angelicae Dahuricae 87g Bulbus Allii Macrostemonis 87g Rhizoma Acori Graminei 87g Radix Salviae Miltiorrhizae 234g
Benzoinum 87g Radix Astragali 87g Radix Paeoniae Rubra 87g Rhizoma Corydalis 87g Caulis Polygoni Multiflori 87g
Semen Cassiae 87g Styrax 234g Borneolum Syntheticum 87g Radix Notoginseng 234g Radix Puerariae 129g;
B) Rhizoma Chuanxiong, Lignum Santali Albi, Radix Curcumae, Flos Caryophylli, Radix Angelicae Sinensis, Rhizoma Acori Graminei, Rhizoma Cyperi, Lignum Dalbergiae Odoriferae, Bulbus Allii Macrostemonis, Lignum Aquilariae Resinatum, Flos Chrysanthemi, the Radix Angelicae Dahuricae, Olibanum, Myrrha Chinese crude drug are used heating decocting in water 10～12 hours, the volatile oil that extractive distillation goes out (water cooking liquid filtration) filtrate is condensed into thick paste, adding amount of alcohol is that 60% composition is stirred to fully evenly, left standstill 24 hours, draw supernatant, the precipitation part filters filtrate decompression, reclaim ethanol, it is standby that reheat is condensed into thick paste;
C) Radix Salviae Miltiorrhizae, the Radix Astragali, Radix Paeoniae Rubra, Radix Puerariae, Benzoinum, Rhizoma Corydalis Chinese medicine are added 9 times of amount ethanol extractions 2 times, each 1 hour, filter the back twice filtrate is merged decompression, reclaim ethanol, it is standby that medicinal liquid is condensed into thick paste;
D) Caulis Polygoni Multiflori and Semen Cassiae 2 flavor medicines according to fluid extracts and extractum item percolation down, during with the alcohol dipping 24 of 12 times of amounts, carry out percolation, the collection percolate, recovery ethanol, it is standby to be condensed into thick paste;
D) it is standby Borneolum Syntheticum and Radix Notoginseng powder to be broken into attritive powder, and Styrax is standby;
E) with step b), c) and d) above-mentioned thick paste and Borneolum Syntheticum powder, Radix Notoginseng powder, the abundant mixing and stirring of Styrax, produce to there being minute bubbles, left standstill 10～30 minutes, promptly get compound;
F) the compound 68% that obtains in the above-mentioned steps, polyvinyl alcohol 25% and glycerol 7%, the three fully mixes stirring, does not produce or the minute bubbles complete obiteration to there being minute bubbles, leaves standstill 20～30 minutes;
G) get the mixing thick paste that above-mentioned steps makes and evenly be coated with fabric film, behind the dry forming, cut into strip 6cm * 5cm * 0.12cm under the room temperature, place on the adhesive-bonded fabric dressing and fix according to the both sides fixed form with film-making machine;
H) at pastille pad pasting layer opposite side sticking glass paper, the commodity of this Chinese medicine pad pasting pericardium pad pasting of protecting by name.
Embodiment 2. prevents and treats guarantor's pericardium pad pasting Transdermal absorption normal to rabbit and operation skin of coronary heart disease and tests
Protect " ferulic acid ", " Borneolum Syntheticum " in the pericardium pad pasting medicine, " Cortex Cinnamomi perfume (or spice) " usefulness
3Behind the H isotopic labeling, join respectively and protect in the pericardium pad pasting medicine, be used for rabbit abdominal part center skin (complete sum operation) outward, regularly get blood, on dual pathways liquid scintillation instrument, count (cpm value), result: 1. protect the pericardium pad pasting with heterogeneous measurement method
3The H-cinnamic acid,
3After H-Borneolum Syntheticum and ferulic acid spread on the rabbit skin outward, all can be very fast by skin absorbs, external application promptly had radioactivity in the blood in 1 hour, can keep more than 24 hours.2. protect the pericardium pad pasting
324 hours absorbtivity of experiment intact skin accounts for more than 3.26% of total external application amount in the H-cinnamic acid body; Operation skin 24 hours absorbtivity accounts for 4.32% of total external application amount, Duo 24.5% (because of the drainage of residual quantity during each is organized in the body and defecation is not counted) than the absorbtivity of intact skin; 24 hours transdermal amount of experiment in vitro accounts for 11.66% of external application amount.3. protect in the pericardium pad pasting
324 hours absorbtivity of experiment intact skin accounts for more than 3.15% of total external application amount in the H-Borneolum Syntheticum body; Operation skin 24 hours absorbtivity accounts for 3.84% of total external application amount, Duo 18% (because of the drainage of residual quantity during each is organized in the body and defecation is not counted) than the intact skin absorbtivity; 24 hours transdermal amount of in vitro tests accounts for 7.39% of total external application amount.4. protect the pericardium pad pasting
324 hours absorbtivity of experiment intact skin accounts for more than 4.66% of total external application amount in the H-ferulic acid body; Operation skin 24 hours absorbtivity accounts for 6.75% of total external application amount, Duo 31% (because of the drainage of residual quantity during each is organized in the body and defecation is not counted) than the absorbtivity of intact skin; 24 hours transdermal amount of experiment in vitro accounts for 13.70% of external application amount.5. description of test is protected pericardium pad pasting medicine external preparation for skin, and its active ingredient can be passed through skin absorbs, holds time more than 24 hours.
Embodiment 3. thin layer chromatography detect the rabbit transdermal and receive the main component test of protecting the pericardium pad pasting in the liquid pool
Select active ingredient cinnamic acid, Borneolum Syntheticum and the ferulic acid protected in the pericardium pad pasting prescription for use, warp
3Be added in behind the H isotopic labeling on the free skin flap that is affixed on the rabbit band base of a fruit on the pad pasting together, be placed on the receipts liquid pool that fills with normal saline, normal saline after the drug of topical application in the regular collecting pit, survey its cpm value, after the drug of topical application 24 hours, it is collected liquid carry out extraction separation, adopt thin layer chromatography (TLC method) to separate and detect the transdermal situation of above-mentioned each composition in the receipts liquid pool, (do not use with standard substance by chemical method
3H carries out the pure product of labelling) contrast with plate, launch back relatively spot and R f value size, the depth, scrape corresponding sample point then, adopt heterogeneous measurement method, counting (cpm value) on the dual pathways liquid scintillation instrument further confirm the active ingredient cinnamic acid, Borneolum Syntheticum, ferulic acid of this medicine through skin the time whether with
3The H isotope breaks away from.Result: 1. by respectively visible in the thin-layer chromatogram
3The component of H-labelling all has Transdermal absorption in various degree, and identical with the thin layer behavior unanimity (Rf value) of standard reference material.2. on the chromatograph except that the composition of labelling, other fat-soluble composition also has absorption in various degree in the preparation, is a plurality of speckles on the chromatograph.The thin layer chromatography behavior of 3. parallel four duplicate samples, spot size, the depth are basic identical, and the illustration method repeatability is better.4. institute's labelling component speckle is scraped handle the back with heterogeneous measurement method on dual pathways liquid scintillation instrument, count the cpm value (
3H-cinnamic acid 54.399 ± 10.101,
3H-Borneolum Syntheticum 2.365 ± 0.409,
3H-ferulic acid 4.8147 ± 5.989), further confirm not come off after mark substance sees through skin with isotope.
Claims (16)
1. membranous patch, it is made up of back lining materials, protecting film and medicated layer, it is characterized in that medicated layer and back lining materials just have adhesive to fix medicated layer at two edges of medicated layer, and two other edge does not have adhesive; Perhaps back lining materials only around medicated layer fixed point rather than four limits have adhesive to fix medicated layer, these fixed points comprise four angle points and every limit mid point or on every limit more multiple spot are arranged.
2. according to the described membranous patch of claim 1, wherein medicated layer is made up of matrix type adjuvant, effective ingredient and plasticizer, wherein contained matrix type adjuvant 20-30%, contained drug active ingredient 60～75%, contained plasticizer 5-10%.
3. according to the described membranous patch of claim 2, it is characterized in that wherein contained matrix type adjuvant 23-25%, contained drug active ingredient 68～70%, contained plasticizer 6-8%.
4. according to the described membranous patch of claim 3, it is characterized in that wherein contained matrix type adjuvant 24%, contained drug active ingredient 70%, contained plasticizer 6%.
5. according to any one described membranous patch among the claim 2-4, matrix type adjuvant wherein is natural polysaccharide and in synthetic polymer such as polyvinyl alcohol, Pioloform, polyvinyl acetal, polyvinylpyrrolidone, polyacrylate or the polyacrylamide one or more.
6. according to the described membranous patch of claim 5, matrix type adjuvant wherein is a polyvinyl alcohol.
7. according to any one the described membranous patch among the claim 2-7, effective ingredient wherein is chemical compound or the active ingredient of Chinese herbs with therapeutical effect.
8. according to the described membranous patch of claim 7, effective ingredient wherein is single medicinal material or kinds of traditional Chinese medicines.
9. according to the described membranous patch of claim 8, Chinese medicine hidden by list wherein or kinds of traditional Chinese medicines is that millimeter is to nano level powder.
10. according to the described membranous patch of claim 8, effective ingredient wherein is the extract of single medicinal material or kinds of traditional Chinese medicines.
11. according to any one described membranous patch among the claim 2-10, plasticizer wherein is one or more in glycerol, triacetyl glycerine, ethylene glycol, the sorbitol phthalic acid ester.
12. according to the described membranous patch of claim 11, plasticizer wherein is a glycerol.
13. the preparation method of the described membranous patch of claim 1, it is characterized in that it is only two parallel edges of medicated layer to be sticked with glue agent to be fixed on the back lining materials, perhaps fixed point around the medicated layer is comprised four angle points and every limit mid point or on there is more multiple spot on every limit, stick with glue agent being fixed on the back lining materials.
14. the preparation method of any one described membranous patch among the claim 2-11, it comprises the following steps:
A) effective ingredient, matrix type adjuvant and plasticizer three are mixed, stir, do not produce or the minute bubbles complete obiteration, left standstill 20 ~ 30 minutes, promptly get and mix thick paste to there being minute bubbles;
B) get the mixing thick paste, put in the film-making machine medicine groove and make film, the film 0.13～0.5cm that is added to, 25 ℃ of-40 ℃ of dryings, medicated layer is made in cutting, place on the back lining materials, sticking with glue agent has more multipoint system fix with the parallel both sides of medicated layer or four angle points and every limit mid point or on every limit;
C) paste protecting film at the medicated layer another side.
15. according to the described preparation method of claim 14, wherein making film forming medicated layer baking temperature is 35 ℃.
16., also be included in before the preparation pulverizing of Chinese medicine ground to form millimeter to nano level powder or extract and obtain extract according to claim 14 or 15 described preparation methoies.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02146525 CN1218693C (en) | 2002-10-21 | 2002-10-21 | Adhesive film agent and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02146525 CN1218693C (en) | 2002-10-21 | 2002-10-21 | Adhesive film agent and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1491642A true CN1491642A (en) | 2004-04-28 |
| CN1218693C CN1218693C (en) | 2005-09-14 |
Family
ID=34232773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02146525 Expired - Lifetime CN1218693C (en) | 2002-10-21 | 2002-10-21 | Adhesive film agent and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1218693C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813793A (en) * | 2012-08-10 | 2012-12-12 | 高文英 | Pill for treating angina pectoris |
| CN103495155A (en) * | 2013-09-25 | 2014-01-08 | 南阳市汇博生物技术有限公司 | Film for hyperplastic scar repair and preparation method thereof |
| CN103689961A (en) * | 2012-09-27 | 2014-04-02 | 赵成喜 | Mattress for treating hypertension and heart disease |
| CN103690520A (en) * | 2013-12-30 | 2014-04-02 | 沈阳药科大学 | Patch containing essential oil of single leaf asarum, as well as preparation method and medical application of patch |
| CN104784627A (en) * | 2015-02-06 | 2015-07-22 | 肖琼 | Traditional Chinese medicine externally used film agent used for treatment surgical open or closed injury and preparation method thereof |
| CN108434288A (en) * | 2018-06-18 | 2018-08-24 | 马南行 | A kind of composition for heart disease prevention and treatment |
-
2002
- 2002-10-21 CN CN 02146525 patent/CN1218693C/en not_active Expired - Lifetime
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813793A (en) * | 2012-08-10 | 2012-12-12 | 高文英 | Pill for treating angina pectoris |
| CN103689961A (en) * | 2012-09-27 | 2014-04-02 | 赵成喜 | Mattress for treating hypertension and heart disease |
| CN103495155A (en) * | 2013-09-25 | 2014-01-08 | 南阳市汇博生物技术有限公司 | Film for hyperplastic scar repair and preparation method thereof |
| CN103495155B (en) * | 2013-09-25 | 2015-10-14 | 南阳市汇博生物技术有限公司 | For pad pasting that hypertrophic cicatrix is repaired and preparation method thereof |
| CN105250995A (en) * | 2013-09-25 | 2016-01-20 | 南阳市汇博生物技术有限公司 | Hyperplastic scar repair plaster and preparing method thereof |
| CN105250995B (en) * | 2013-09-25 | 2018-06-22 | 河南汇博医疗股份有限公司 | Hyperplastic scar repairs pad pasting and preparation method thereof |
| CN103690520A (en) * | 2013-12-30 | 2014-04-02 | 沈阳药科大学 | Patch containing essential oil of single leaf asarum, as well as preparation method and medical application of patch |
| CN104784627A (en) * | 2015-02-06 | 2015-07-22 | 肖琼 | Traditional Chinese medicine externally used film agent used for treatment surgical open or closed injury and preparation method thereof |
| CN104784627B (en) * | 2015-02-06 | 2018-05-22 | 肖琼 | It is a kind of to be used to treat Chinese medicine external film of surgery opening or closed injury and preparation method thereof |
| CN108434288A (en) * | 2018-06-18 | 2018-08-24 | 马南行 | A kind of composition for heart disease prevention and treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1218693C (en) | 2005-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110917243B (en) | Gel paste containing plant extract and preparation method thereof | |
| CN102406794A (en) | Transdermal administered gel ointment containing rhizoma ligustici wallichii and nutgrass galingale rhizome | |
| CN110742993A (en) | Pain-relieving and swelling-diminishing plaster and preparation method and application thereof | |
| CN1218693C (en) | Adhesive film agent and its preparing method | |
| CN101732668B (en) | Preparation method of Chinese medicinal composition for treating urinary system infection | |
| CN1647803A (en) | Chinese medicine composition plaster for external anti-inflammation and analgetics | |
| CN1262299C (en) | Chinese medicine adhesive film for preventing and treating coronary heart disease and angina pectoris and its preparing method | |
| CN104274546A (en) | Externally-applied traditional Chinese medicine composition, externally-applied traditional Chinese medicine preparation as well as preparation method and application of externally-applied traditional Chinese medicine composition | |
| CN101933973B (en) | Medicament composition for preventing and treating liver damage | |
| CN100502880C (en) | Notoginseng glycol-saponin composition and its preparation method and use | |
| CN101564487A (en) | Jiehong medicine for injuries from falls and preparation method thereof | |
| CN101850094A (en) | Chinese medicinal adhesive plaster | |
| CN102302616B (en) | Cataplasm for treating knee osteoarthritis and preparation method thereof | |
| CN111956721B (en) | Allergic rhinitis acupoint plaster and preparation method thereof | |
| CN103417941A (en) | Hydrogel transdermal patch for preventing congealing cold blood stasis-type primary dysmenorrheal, and preparation method of hydrogel transdermal patch | |
| CN101274037B (en) | Detection method of composition for curing skin pruritus | |
| CN110141622B (en) | Traditional Chinese medicine composition for treating pain and preparation method and application thereof | |
| CN101711857B (en) | Film coating agent for treating whitevein and preparation method thereof | |
| CN101474315B (en) | Effective component group of stem-bark or root-bark of Daphne giraldii as well as preparation method and use thereof | |
| CN1903314A (en) | Traditional Chinese medicine composition for treating head-ache, ahypnia, palpitate and feeble, and its prepn. method | |
| CN102755396A (en) | Preparation process and matrix for gel cream for treating coronary heart disease | |
| CN107875182A (en) | Heiguteng exract active principle and its preparation method and application | |
| CN110251638B (en) | Dark green ginger fever gel paste for treating myofascitis and preparation method thereof | |
| CN1268362A (en) | Compound Chinese herb medicine for curing fibrosis of liver and hepatocirrhosis and its preparation method | |
| CN100444829C (en) | Freeze-dry snow lotus powder for venous injection and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING HUAHENGHANFANG PHARMACEUTICAL TECHNOLOGY C Free format text: FORMER OWNER: MA DELIN Effective date: 20090807 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090807 Address after: Room 21, No. 427, torch street, Changping District science and Technology Park, Beijing Patentee after: Beijing Huaheng Hanfang Pharmaceutical Technology Co.,Ltd. Address before: The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, 117 Mei Shan Road, Anhui, Hefei, China Patentee before: Ma Delin |
|
| C56 | Change in the name or address of the patentee |
Owner name: BEIJING HUAHENG HANFANG PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: |
|
| CP03 | Change of name, title or address |
Address after: 102200, room 219, block B, No. 9, front road, Changping District science and Technology Park, Beijing Patentee after: Beijing Huaheng Hanfang Pharmaceutical Co.,Ltd. Address before: 102200, room 21, 427 torch street, Changping District science and Technology Park, Beijing Patentee before: Beijing Huaheng Hanfang Pharmaceutical Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20220810 Address after: 230000 Room 203, building 5, No. 70, Meishan Road, Shushan District, Hefei City, Anhui Province Patentee after: Ma Delin Address before: 102200 room 219, block B, No.9 Chaoqian Road, science and Technology Park, Changping District, Beijing Patentee before: Beijing Huaheng Hanfang Pharmaceutical Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CX01 | Expiry of patent term |
Granted publication date: 20050914 |
|
| CX01 | Expiry of patent term |